Page last updated: 2024-11-07

calpain inhibitor 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

calpain inhibitor 2: inhibits degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and some other cysteine proteinases [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121855
CHEMBL ID318779
CHEBI ID7209
SCHEMBL ID2162504
MeSH IDM0190515

Synonyms (39)

Synonym
chebi:7209 ,
CHEMBL318779 ,
ac-leu-leu-met-h
n-acetyl-l-leucyl-n-(1-formyl-3-mercaptopropyl)-l-leucinamide (s)
calpain inhibitor ii
110115-07-6
n-acetylleucyl-leucyl-methioninal
calpain inhibitor ii, powder
allm
cpi(2)
n-acetyl-leu-leu-methioninal
n-allm
calpain inhibitor 2
l-leucinamide, n-acetyl-l-leucyl-n-(1-formyl-3-(methylthio)propyl)-, (s)-
suam-312
n-acetyl-l-leucyl-l-leucyl-l-methioninal
(2s)-2-acetamido-4-methyl-n-[(2s)-4-methyl-1-[[(2s)-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]pentanamide
SCHEMBL2162504
ac-leu-leu-l-methioninal
unii-1d8sbu367z
1d8sbu367z ,
allm (calpain inhibitor)
l-leucinamide, n-acetyl-l-leucyl-n-((1s)-1-formyl-3-(methylthio)propyl)-
ci 2
bdbm50421409
CCG-207842
(2s)-2-acetamido-n-[(1s)-1-[[(1s)-1-formyl-3-methylsulfanyl-propyl]carbamoyl]-3-methyl-butyl]-4-methyl-pentanamide
n-acetylleucyl-leucyl-methininal
2-[(1-hydroxyethylidene)amino]-n-(1-hydroxy-4-methyl-1-{[4-(methylsulfanyl)-1-oxobutan-2-yl]imino}pentan-2-yl)-4-methylpentanimidic acid
DTXSID90911499
allm - cas 110115-07-6
mfcd00065506
Q27107457
HY-118355
A14911
(s)-2-acetamido-4-methyl-n-((s)-4-methyl-1-((s)-4-(methylthio)-1-oxobutan-2-ylamino)-1-oxopentan-2-yl)pentanamide
CS-0065741
ac-leu-leu-methional; allm
AKOS040741088
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calpain-9Homo sapiens (human)IC50 (µMol)3.32001.61003.97609.8800AID1620950
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
digestionCalpain-9Homo sapiens (human)
proteolysisCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
calcium ion bindingCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cellular_componentCalpain-9Homo sapiens (human)
cytoplasmCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID343738Inhibition of trypsin-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID513660Induction of autophagy in african green monkey COS7 cells assessed as increase in LC3-2 vesicle at 50 uM after 24 hrs by immunofluorescence assay2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID1675002Inhibition of SARS-CoV-2 main protease expressed in expressed in BL21(DE3) Escherichia Coli assessed as reduction in viral replication by FRET assay2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
The SARS-CoV-2 main protease as drug target.
AID590339Inhibition of chymotrypsin-like activity of 20S proteasome2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and proteasome inhibition of lithocholic acid derivatives.
AID1891409Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate at 100 uM incubated for 30 mins by FRET based assay relative to control
AID621520Inhibition of human 20S proteasome chymotrypsin-like activity using Suc-Leu-Leu-Val-Tyr-AMC fluorogenic substrate by fluorimetry2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
New betulinic acid derivatives as potent proteasome inhibitors.
AID343739Inhibition of caspase-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID513664Induction of autophagy in human HeLa cells expressing EGFP-LC3 assessed as increase in LC3-2 level at 50 uM in presence of 400 nM bafilomycin A12008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID343737Inhibition of chymotrypsin-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (29.85)18.2507
2000's31 (46.27)29.6817
2010's12 (17.91)24.3611
2020's4 (5.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.81 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (98.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]